Editorial: New Insights into Caring for Pediatric Patients with Cystic Fibrosis

Overview

Journal Front Pediatr

Specialty Pediatrics

Date 2023 Aug 28

PMID 37635799

Authors

Stephanie Bui

Laurence Delhaes

Gael Dournes

Philippe Reix

Michael John Fayon

Affiliations

Soon will be listed here.

References

Reix P, Tatopoulos A, Ioan I, Le Bourgeois M, Bui S, Choukroun M . Real-world assessment of LCI following lumacaftor-ivacaftor initiation in adolescents and adults with cystic fibrosis. J Cyst Fibros. 2021; 21(1):155-159. DOI: 10.1016/j.jcf.2021.06.002. View

Hanrahan J, Sampson H, Thomas D . Novel pharmacological strategies to treat cystic fibrosis. Trends Pharmacol Sci. 2013; 34(2):119-25. DOI: 10.1016/j.tips.2012.11.006. View

De Boeck K . Cystic fibrosis in the year 2020: A disease with a new face. Acta Paediatr. 2020; 109(5):893-899. DOI: 10.1111/apa.15155. View

Nichols D, Paynter A, Heltshe S, Donaldson S, Frederick C, Freedman S . Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial. Am J Respir Crit Care Med. 2021; 205(5):529-539. PMC: 8906485. DOI: 10.1164/rccm.202108-1986OC. View

De Boeck K, Zolin A . Year to year change in FEV in patients with cystic fibrosis and different mutation classes. J Cyst Fibros. 2016; 16(2):239-245. DOI: 10.1016/j.jcf.2016.09.009. View

Bui S, Macey J, Fayon M, Bihouee T, Burgel P, Colomb V . [New therapeutic developments in cystic fibrosis]. Arch Pediatr. 2017; 23(12S):12S47-12S53. DOI: 10.1016/S0929-693X(17)30062-3. View

Stephenson A, Stanojevic S, Sykes J, Burgel P . The changing epidemiology and demography of cystic fibrosis. Presse Med. 2017; 46(6 Pt 2):e87-e95. DOI: 10.1016/j.lpm.2017.04.012. View

Lubamba B, Dhooghe B, Noel S, Leal T . Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy. Clin Biochem. 2012; 45(15):1132-44. DOI: 10.1016/j.clinbiochem.2012.05.034. View

Burgel P, Munck A, Durieu I, Chiron R, Mely L, Prevotat A . Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis. Am J Respir Crit Care Med. 2019; 201(2):188-197. DOI: 10.1164/rccm.201906-1227OC. View

10.

Smyth A, Bell S, Bojcin S, Bryon M, Duff A, Flume P . European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. J Cyst Fibros. 2014; 13 Suppl 1:S23-42. DOI: 10.1016/j.jcf.2014.03.010. View

11.

Mall M, Brugha R, Gartner S, Legg J, Moeller A, Mondejar-Lopez P . Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study. Am J Respir Crit Care Med. 2022; 206(11):1361-1369. PMC: 9746869. DOI: 10.1164/rccm.202202-0392OC. View

12.

Farrell P, White T, Ren C, Hempstead S, Accurso F, Derichs N . Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation. J Pediatr. 2017; 181S:S4-S15.e1. DOI: 10.1016/j.jpeds.2016.09.064. View

13.

Bui S, Masson A, Enaud R, Roditis L, Dournes G, Galode F . Long-Term Outcomes in Real Life of Lumacaftor-Ivacaftor Treatment in Adolescents With Cystic Fibrosis. Front Pediatr. 2021; 9:744705. PMC: 8634876. DOI: 10.3389/fped.2021.744705. View

14.

Turck D, Braegger C, Colombo C, Declercq D, Morton A, Pancheva R . ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. Clin Nutr. 2016; 35(3):557-77. DOI: 10.1016/j.clnu.2016.03.004. View